Advanced Biomarkers: Therapeutic and Diagnostic Targets in Urticaria

Int Arch Allergy Immunol. 2021;182(10):917-931. doi: 10.1159/000515753. Epub 2021 Apr 29.

Abstract

Urticaria is a type of skin disease characterized by rapid onset of hives (superficial dermis edema, erythema, pruritus, or burning sensation). According to whether the natural course exceeds 6 weeks, urticaria can be divided into acute and chronic urticaria (CU). At present, the evaluation of CU activity mainly depends on the Urticaria Activity Score (UAS), but the evaluation indicators are relatively single, and we need more reliable experimental data for evaluation. We typically summarize advanced biomarkers and several related pathogenic pathways discovered in recent years on urticaria, including the cell adhesion/chemotaxis pathway, interleukin (IL)-6/Janus tyrosine kinase/STAT pathway, IL-17/IL-23 pathway, basophil- and mast cell-related pathway, coagulation/fibrinolysis-related pathways, single-nucleotide polymorphism, and some other pathways. This review aims to find appropriate biomarkers so that we can evaluate disease activity, discover novel therapeutic targets, and predict the patients' response more accurately to therapeutic agents.

Keywords: Basophils; Biomarkers; Mast cells; Single-nucleotide polymorphism; Urticaria.

Publication types

  • Review

MeSH terms

  • Animals
  • Basophils / immunology
  • Biomarkers
  • Blood Coagulation
  • Cell Adhesion
  • Chemotaxis
  • Cytokines / immunology
  • Humans
  • Mast Cells / immunology
  • Polymorphism, Single Nucleotide
  • Urticaria / diagnosis*
  • Urticaria / genetics
  • Urticaria / immunology
  • Urticaria / therapy*

Substances

  • Biomarkers
  • Cytokines